The next generation biopharmaceuticals

Projects Affibody's pipeline

Affibody is strategically focused on advancing our pipeline of radioligand therapeutics that offer a competitive advantage and significant opportunities to benefit cancer patients. Our pipeline also includes partnership programs in immunology.

Pipeline

Affibody Upcoming events

event

3 Jun

EULAR 2026 June 3-6, 2026, London, UK

event

22 Jun

BIO International Convention June 22-25, 2026, San Diego, USA

event

21 Jul

The 5th Targeted Radiopharmaceuticals Summit US July 21 – 23, 2026, San Diego, USA

There are currently no posts in the reports and events archive.

About Affibody Further Information

Our R&D focus on radioligand therapeutics

Latest news from Affibody

Regulatory

2026-05-28

First Patient Dosed in Part B of Phase 1 Study with Affibody’s Radioligand Therapy Candidate ABY-271 in HER2-positive Metastatic Breast Cancer

Stockholm, Sweden, May 28, 2026. Affibody AB (“Affibody”) today announced that the first patient has been dosed in part B of a Phase 1...[read more]

Previous press & news

Regulatory

2026-05-27

Affibody Presents First-in-Human Clinical Imaging Data with ABY-271 in HER2-positive Metastatic Breast Cancer at SNMMI 2026

Stockholm, Sweden, May 27, 2026. Affibody AB (“Affibody”) today announced that initial first-in-human clinical imaging...[read more]

Regulatory

2026-05-25

Report from Annual General Meeting in Affibody Medical AB (publ)

Stockholm, Sweden, May 25, 2026 – Affibody Medical AB (publ) today held its Annual General...[read more]

All press & news

Career Work at Affibody

It is the competence and the engagement of all coworkers that make Affibody an inspiring and exciting place to work at. We know we reach much further in innovation, efficiency, and quality by having a work place where we as coworkers care for each other, are ambitious and know and value our own contribution to the end result.

Career